NASDAQ: MEDS
Datameds Ai Inc Earnings Dates, Reports, Calls

Datameds Ai earnings were -$88.3M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest MEDS earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$18.4M, up 137.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MEDS reported annual earnings of -$101.3M, with 1,377.1% growth.

MEDS earnings history

Current Revenue
$8.0M
Current Earnings
-$88.3M
Current Profit Margin
-1,100.3%

MEDS Return on Equity

Current Company
N/A
Current Industry
-71.7%
Current Market
31.1%

MEDS Return on Assets

Current Company
-241.6%
Current Industry
-62.3%
MEDS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MEDS announces earnings.

MEDS Return on Capital Employed

Current Company
1,237.41%
Current Industry
59.6%

MEDS vs Pharmaceutical Retailer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MEDS-$80.02M-$88.28MN/A-$46.63
HKPD-$307.33k-$1.14MN/A-$0.07
RDGT-$918.77k-$1.25MN/A-$17.21
POM-$17.34M-$31.26MN/A-$9.71
SCNX-$35.49M-$37.95MN/A-$2.10

Datameds Ai Earnings Reports & History FAQ

What were Datameds Ai's earnings last quarter?

On MEDS's earnings call on Aug 18, 2026, Datameds Ai (NASDAQ: MEDS) reported Q2 2026 earnings per share (EPS) of -$7.13, up 32.04% year over year. Total MEDS earnings for the quarter were -$18.36 million. In the same quarter last year, Datameds Ai's earnings per share (EPS) was -$5.40.

If you're new to stock investing, here's how to buy Datameds Ai stock.

Is Datameds Ai profitable or losing money?

As of the last Datameds Ai earnings report, Datameds Ai is currently losing money. Datameds Ai's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$88.28 million, a 94.86% increase year over year.

What was MEDS's earnings growth in the past year?

As of Datameds Ai's earnings date in Aug 18, 2026, Datameds Ai's earnings has grown year over year. MEDS earnings in the past year totalled -$88.28 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.